Health Market International "Pharmaco-Economics"

	Medication therapy for patients with coronary ischemia has been continually presented as an alternative to angioplasty and potential bypass surgeries. HMI has performed costing studies on cardiac procedures in over 20 countries to evaluate the cost effectiveness of treatment patterns and shifts in cost of care.
	The combination of the aging population, growing concerns with osteoporosis, and the adverse effects of hormone replacement therapy were key determinants for the development and market acceptance of the Merck & Co, medication FOSAMAX™. HMI has been instrumental in determining the cost of care in treating hip fractures related to osteoporosis in North America, Europe, Asia, and Africa. The HMI projects have assisted Merck offices with the introduction and approval of FOSAMAX in their respective countries.
	The introduction of protease inhibitors for the treament of HIV infected patients has made a significant impact on the prognosis of the dreaded disease. HMI has initiated studies to determine the cost of caring for HIV patients at various stages of the disease and across various healthcare settings. The impact from HMI's study has already assisted the approvals of this important medication and will certainly influence the future acceptance in other countries worldwide.
	The use of various international grouping methodologies such as DRGs, HRGs, CMGs, and GHMs provide substantial information related to hospital utilisation, length of stay, and general cost of patient care. The proper use of these grouping methodologies require an international level of expertise which ensures consistency and accuracy. HMI has provided numerous studies in many different international classifications and grouping methodologies to assess market potential and patient outcomes.

---